MeiraGTx Holdings plc (MGTX)
NASDAQ: MGTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MGTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $779.89M
- P/E (TTM)
- 9.17
- EPS (TTM)
- $0.87
- Dividend yield
- None
- 52-week range
- 6.62 – 15.35
- Day range
- 7.81 – 8.23
- Volume / Avg
- 1.01M / 837.25K
- Beta
- —
- Shares outstanding
- 97.73M
52-week range
MGTX stock today
Shares of MeiraGTx (MGTX) finished lower on Nov 20 at $7.98, a drop of 1.97% or $0.16 per share, versus the S&P 500's 3.70% decline. At this level, MGTX sits near the bottom of its 52-week range of $6.62 to $15.35: 48.0% below the high, set on Jul 7, 2026 and 20.5% above the low. MGTX is up 0.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 7.0%.
MeiraGTx trades at 9.2x its trailing twelve-month earnings per share of $0.87.
Summary generated from market data by MetaCap's automated system. Methodology
About MeiraGTx
Company profileMeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase ½ clinical trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Alexandria Forbes Ph.D.
- Headquarters
- New York, NY
- Employees
- 386
- IPO year
- 2018
- Website
- meiragtx.com
Financial highlights
Full financialsIn fiscal 2025, MeiraGTx generated $81.4 million in revenue, up 144.6% from fiscal 2024, its 2nd consecutive year of revenue growth. MeiraGTx reported a net loss of $114.2 million, compared with a loss of $147.8 million a year earlier. Operating margin was -130.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $81.39M | $33.28M | $14.02M | $15.92M | $37.70M |
| Growth | +144.57% | +137.42% | -11.95% | -57.77% | +142.25% |
| Net income | $-114.20M | $-147.79M | $-84.03M | $-129.62M | $-79.56M |
| EPS (diluted) | $-1.42 | $-2.12 | $-1.49 | $-2.87 | $-1.80 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$27.75+247.74%
- Strong buy 2
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.53 vs $-0.46
- Surprise
- -15.22%
MGTX news
All MGTX news- MeiraGTx Announces Oral Presentation at ObesityWeek 2026GlobeNewswire
- MeiraGTx Holdings plc Reports Third Quarter 2026 Financial and Operational ResultsNasdaq
- MeiraGTx GAAP EPS of -$0.53 misses by $0.03, revenue of $4.81M misses by $2.21MSeeking Alpha
- MeiraGTx Reports Third Quarter 2026 Financial and Operational ResultsGlobeNewswire
- MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual MeetingGlobeNewswire
- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.NasdaqPTGX, JNJ, LAB, XNCR
MeiraGTx peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRMEPrime Medicine Inc. | 3.55 | -7.55% | $791.62M | vs MGTX |
| BBTXBambusa Therapeutics Inc. | 16.00 | +2.89% | $815.08M | vs MGTX |
| ODTXOdyssey Therapeutics Inc. | 16.96 | -7.52% | $815.23M | vs MGTX |
| GLUEMonte Rosa Therapeutics Inc. | 8.64 | -3.03% | $738.29M | vs MGTX |
| AURAAura Biosciences Inc. | 6.87 | -1.58% | $714.99M | vs MGTX |
| IMTXImmatics N.V. | 5.77 | -3.03% | $878.58M | vs MGTX |
| SLDBSolid Biosciences Inc. | 6.25 | -2.95% | $697.57M | vs MGTX |
| ATTOAttovia Therapeutics Inc. | 15.10 | -3.08% | $690.26M | vs MGTX |
Indexes, lists and sector
MeiraGTx stock FAQ
What is MeiraGTx's stock price today?
MGTX last traded at $7.98 as of Nov 20, 4:00 PM EST, down 1.97% on the day. Prices are delayed at least 15 minutes.
What is MGTX's P/E ratio?
MGTX trades at a trailing P/E ratio of 9.17.
Who is MeiraGTx's CEO?
Dr. Alexandria Forbes Ph.D. is the chief executive officer of MeiraGTx Holdings plc, which has about 386 employees.
What is the MGTX 52-week high?
The 52-week high for MGTX is $15.35 and the 52-week low is $6.62. The stock is currently 48.0% below its high.